...
首页> 外文期刊>BMC Genomics >A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samples
【24h】

A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samples

机译:可靠评估外显子表达,以鉴定适用于人体组织和癌症样品的可变剪接基因

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Accurate analysis of whole-gene expression and individual-exon expression is essential to characterize different transcript isoforms and identify alternative splicing events in human genes. One of the omic technologies widely used in many studies on human samples are the exon-specific expression microarray platforms. Results Since there are not many validated comparative analyses to identify specific splicing events using data derived from these types of platforms, we have developed an algorithm (called ESLiM) to detect significant changes in exon use, and applied it to a reference dataset of 270 human genes that show alternative expression in different tissues. We compared the results with three other methodological approaches and provided the R source code to be applied elsewhere. The genes positively detected by these analyses also provide a verified subset of human genes that present tissue-regulated isoforms. Furthermore, we performed a validation analysis on human patient samples comparing two different subtypes of acute myeloid leukemia (AML) and we experimentally validated the splicing in several selected genes that showed exons with highly significant signal change. Conclusions The comparative analyses with other methods using a fair set of human genes that show alternative splicing and the validation on clinical samples demonstrate that the proposed novel algorithm is a reliable tool for detecting differential splicing in exon-level expression data.
机译:背景完整基因表达和单个外显子表达的准确分析对于表征不同转录本亚型和鉴定人类基因中的可变剪接事件至关重要。外显子特异性表达微阵列平台是在人类样品的许多研究中广泛使用的omic技术之一。结果由于没有足够的经过验证的比较分析来使用这些类型的平台中的数据识别特定的剪接事件,因此我们开发了一种算法(称为ESLiM)来检测外显子使用的重大变化,并将其应用于270个人的参考数据在不同组织中显示出替代表达的基因。我们将结果与其他三种方法学方法进行了比较,并提供了可在其他地方应用的R源代码。通过这些分析阳性检测的基因还提供了人类基因的经过验证的子集,这些子集呈现出组织调节的同工型。此外,我们对人类患者样品进行了验证分析,比较了两种不同的急性髓细胞白血病(AML)亚型,并通过实验验证了几个选定基因的剪接,这些基因显示出具有显着信号变化的外显子。结论使用公平的人类基因集与其他方法进行的比较分析显示了可变剪接,并在临床样品上进行了验证,结果表明,该新算法是检测外显子水平表达数据中差异剪接的可靠工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号